RecruitingPhase 2NCT07037238
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
Sponsor
Xuanwu Hospital, Beijing
Enrollment
10 participants
Start Date
Jul 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Everolimus 10mg daily for people with vascular malformations. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEverolimus 10mg daily
An oral mTOR inhibitor
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07037238
Related Trials
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT0678991334 locations
Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study
NCT061890921 location
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT059831592 locations
Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)
NCT041044641 location
Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
NCT026383893 locations